Does the media refer more to AEHR or CTKB?

In the previous week, Aehr Test Systems had 33 more articles in the media than Cytek Biosciences. MarketBeat recorded 35 mentions for Aehr Test Systems and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.96 beat Aehr Test Systems' score of 0.55 indicating that Cytek Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aehr Test Systems 11 Very Positive mention(s) 4 Positive mention(s) 13 Neutral mention(s) 0 Negative mention(s) 3 Very Negative mention(s) Positive Cytek Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALMR or CTKB?

In the previous week, Cytek Biosciences had 1 more articles in the media than Alamar Biosciences. MarketBeat recorded 2 mentions for Cytek Biosciences and 1 mentions for Alamar Biosciences. Cytek Biosciences' average media sentiment score of 0.96 beat Alamar Biosciences' score of 0.67 indicating that Cytek Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alamar Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytek Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, ALNT or CTKB?

Allient has higher revenue and earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Allient, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Allient $554.48M 2.66 $22.03M $1.43 60.57 Cytek Biosciences $201.49M 2.94 -$66.54M -$0.57 N/A

Does the media prefer ALNT or CTKB?

In the previous week, Allient and Allient both had 2 articles in the media. Allient's average media sentiment score of 1.10 beat Cytek Biosciences' score of 0.96 indicating that Allient is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allient 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytek Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CTKB or EYPT?

In the previous week, Eyepoint Pharmaceuticals had 6 more articles in the media than Cytek Biosciences. MarketBeat recorded 8 mentions for Eyepoint Pharmaceuticals and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.96 beat Eyepoint Pharmaceuticals' score of 0.32 indicating that Cytek Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Eyepoint Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings & valuation, CTKB or TRNS?

Transcat has higher revenue and earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cytek Biosciences $201.49M 2.94 -$66.54M -$0.57 N/A Transcat $331.88M 2.42 $5.38M $0.58 148.43

Does the media favor CTKB or TRNS?

In the previous week, Transcat had 2 more articles in the media than Cytek Biosciences. MarketBeat recorded 4 mentions for Transcat and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.96 beat Transcat's score of 0.90 indicating that Cytek Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cytek Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Transcat 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cytek Biosciences (CTKB) Competitors

$4.58 -0.04 (-0.87%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$4.57 -0.01 (-0.24%)

As of 07/20/2026 07:56 PM Eastern

Compare

CTKB vs. AEHR, ALMR, ALNT, EYPT, and TRNS

Should you buy Cytek Biosciences stock or one of its competitors? MarketBeat compares Cytek Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cytek Biosciences include Aehr Test Systems (AEHR), Alamar Biosciences (ALMR), Allient (ALNT), Eyepoint Pharmaceuticals (EYPT), and Transcat (TRNS). These companies are all part of the "measuring and control equipment" industry.

How does Cytek Biosciences compare to Aehr Test Systems?

Aehr Test Systems (NASDAQ:AEHR) and Cytek Biosciences (NASDAQ:CTKB) are both measuring and control equipment companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.

Aehr Test Systems currently has a consensus target price of $117.50, suggesting a potential upside of 51.89%. Cytek Biosciences has a consensus target price of $5.69, suggesting a potential upside of 24.18%. Given Aehr Test Systems' stronger consensus rating and higher possible upside, equities analysts plainly believe Aehr Test Systems is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aehr Test Systems	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

69.7% of Aehr Test Systems shares are held by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are held by institutional investors. 6.8% of Aehr Test Systems shares are held by insiders. Comparatively, 10.4% of Cytek Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Aehr Test Systems had 33 more articles in the media than Cytek Biosciences. MarketBeat recorded 35 mentions for Aehr Test Systems and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.96 beat Aehr Test Systems' score of 0.55 indicating that Cytek Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aehr Test Systems	11 Very Positive mention(s)	4 Positive mention(s)	13 Neutral mention(s)	0 Negative mention(s)	3 Very Negative mention(s)	Positive
Cytek Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Aehr Test Systems has a net margin of -14.25% compared to Cytek Biosciences' net margin of -36.25%. Aehr Test Systems' return on equity of -4.48% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aehr Test Systems	-14.25%	-4.48%	-3.90%
Cytek Biosciences	-36.25%	-10.07%	-7.56%

Aehr Test Systems has a beta of 3.17, indicating that its stock price is 217% more volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.17, indicating that its stock price is 17% more volatile than the broader market.

Aehr Test Systems has higher earnings, but lower revenue than Cytek Biosciences. Aehr Test Systems is trading at a lower price-to-earnings ratio than Cytek Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aehr Test Systems	$50M	48.66	-$7.13M	-$0.24	N/A
Cytek Biosciences	$201.49M	2.94	-$66.54M	-$0.57	N/A

Summary

Aehr Test Systems beats Cytek Biosciences on 12 of the 16 factors compared between the two stocks.

How does Cytek Biosciences compare to Alamar Biosciences?

Alamar Biosciences (NASDAQ:ALMR) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap measuring and control equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability and earnings.

In the previous week, Cytek Biosciences had 1 more articles in the media than Alamar Biosciences. MarketBeat recorded 2 mentions for Cytek Biosciences and 1 mentions for Alamar Biosciences. Cytek Biosciences' average media sentiment score of 0.96 beat Alamar Biosciences' score of 0.67 indicating that Cytek Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alamar Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytek Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alamar Biosciences presently has a consensus price target of $30.00, indicating a potential upside of 25.42%. Cytek Biosciences has a consensus price target of $5.69, indicating a potential upside of 24.18%. Given Alamar Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Alamar Biosciences is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alamar Biosciences	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Alamar Biosciences has a net margin of 0.00% compared to Cytek Biosciences' net margin of -36.25%. Alamar Biosciences' return on equity of 0.00% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alamar Biosciences	N/A	N/A	N/A
Cytek Biosciences	-36.25%	-10.07%	-7.56%

Cytek Biosciences has higher revenue and earnings than Alamar Biosciences. Alamar Biosciences is trading at a lower price-to-earnings ratio than Cytek Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alamar Biosciences	$87.16M	19.02	-$120.60M	-$1.74	N/A
Cytek Biosciences	$201.49M	2.94	-$66.54M	-$0.57	N/A

69.5% of Cytek Biosciences shares are owned by institutional investors. 10.4% of Cytek Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Cytek Biosciences beats Alamar Biosciences on 8 of the 15 factors compared between the two stocks.

How does Cytek Biosciences compare to Allient?

Allient (NASDAQ:ALNT) and Cytek Biosciences (NASDAQ:CTKB) are both small-cap measuring and control equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, risk, profitability, institutional ownership and earnings.

In the previous week, Allient and Allient both had 2 articles in the media. Allient's average media sentiment score of 1.10 beat Cytek Biosciences' score of 0.96 indicating that Allient is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allient	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytek Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

61.6% of Allient shares are owned by institutional investors. Comparatively, 69.5% of Cytek Biosciences shares are owned by institutional investors. 15.0% of Allient shares are owned by insiders. Comparatively, 10.4% of Cytek Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Allient currently has a consensus price target of $79.83, indicating a potential downside of 7.82%. Cytek Biosciences has a consensus price target of $5.69, indicating a potential upside of 24.18%. Given Cytek Biosciences' higher possible upside, analysts plainly believe Cytek Biosciences is more favorable than Allient.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allient	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Allient has a net margin of 4.25% compared to Cytek Biosciences' net margin of -36.25%. Allient's return on equity of 12.47% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allient	4.25%	12.47%	6.37%
Cytek Biosciences	-36.25%	-10.07%	-7.56%

Allient has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market. Comparatively, Cytek Biosciences has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market.

Allient has higher revenue and earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Allient, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allient	$554.48M	2.66	$22.03M	$1.43	60.57
Cytek Biosciences	$201.49M	2.94	-$66.54M	-$0.57	N/A

Summary

Allient beats Cytek Biosciences on 12 of the 15 factors compared between the two stocks.

How does Cytek Biosciences compare to Eyepoint Pharmaceuticals?

Cytek Biosciences (NASDAQ:CTKB) and Eyepoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, media sentiment, dividends, earnings and risk.

69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. 10.4% of Cytek Biosciences shares are owned by insiders. Comparatively, 5.1% of Eyepoint Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cytek Biosciences has a net margin of -36.25% compared to Eyepoint Pharmaceuticals' net margin of -3,566.63%. Cytek Biosciences' return on equity of -10.07% beat Eyepoint Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-36.25%	-10.07%	-7.56%
Eyepoint Pharmaceuticals	-3,566.63%	-110.54%	-90.15%

Cytek Biosciences presently has a consensus price target of $5.69, suggesting a potential upside of 24.18%. Eyepoint Pharmaceuticals has a consensus price target of $43.75, suggesting a potential upside of 245.58%. Given Eyepoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Eyepoint Pharmaceuticals is more favorable than Cytek Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Eyepoint Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

Cytek Biosciences has a beta of 1.17, indicating that its share price is 17% more volatile than the broader market. Comparatively, Eyepoint Pharmaceuticals has a beta of 1.73, indicating that its share price is 73% more volatile than the broader market.

Cytek Biosciences has higher revenue and earnings than Eyepoint Pharmaceuticals. Cytek Biosciences is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	2.94	-$66.54M	-$0.57	N/A
Eyepoint Pharmaceuticals	$31.37M	33.84	-$231.96M	-$3.50	N/A

In the previous week, Eyepoint Pharmaceuticals had 6 more articles in the media than Cytek Biosciences. MarketBeat recorded 8 mentions for Eyepoint Pharmaceuticals and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.96 beat Eyepoint Pharmaceuticals' score of 0.32 indicating that Cytek Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eyepoint Pharmaceuticals	1 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Eyepoint Pharmaceuticals beats Cytek Biosciences on 9 of the 17 factors compared between the two stocks.

How does Cytek Biosciences compare to Transcat?

Cytek Biosciences (NASDAQ:CTKB) and Transcat (NASDAQ:TRNS) are both small-cap measuring and control equipment companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends.

Transcat has a net margin of 1.62% compared to Cytek Biosciences' net margin of -36.25%. Transcat's return on equity of 5.84% beat Cytek Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytek Biosciences	-36.25%	-10.07%	-7.56%
Transcat	1.62%	5.84%	3.78%

69.5% of Cytek Biosciences shares are owned by institutional investors. Comparatively, 98.3% of Transcat shares are owned by institutional investors. 10.4% of Cytek Biosciences shares are owned by company insiders. Comparatively, 2.8% of Transcat shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cytek Biosciences has a beta of 1.17, suggesting that its share price is 17% more volatile than the broader market. Comparatively, Transcat has a beta of 0.69, suggesting that its share price is 31% less volatile than the broader market.

Transcat has higher revenue and earnings than Cytek Biosciences. Cytek Biosciences is trading at a lower price-to-earnings ratio than Transcat, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytek Biosciences	$201.49M	2.94	-$66.54M	-$0.57	N/A
Transcat	$331.88M	2.42	$5.38M	$0.58	148.43

In the previous week, Transcat had 2 more articles in the media than Cytek Biosciences. MarketBeat recorded 4 mentions for Transcat and 2 mentions for Cytek Biosciences. Cytek Biosciences' average media sentiment score of 0.96 beat Transcat's score of 0.90 indicating that Cytek Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cytek Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Transcat	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cytek Biosciences currently has a consensus target price of $5.69, suggesting a potential upside of 24.18%. Transcat has a consensus target price of $105.50, suggesting a potential upside of 22.55%. Given Cytek Biosciences' higher possible upside, analysts clearly believe Cytek Biosciences is more favorable than Transcat.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytek Biosciences	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Transcat	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50

Summary

Transcat beats Cytek Biosciences on 11 of the 17 factors compared between the two stocks.

Get Cytek Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CTKB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CTKB vs. The Competition

Export

Metric	Cytek Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$596.64M	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-8.03	20.49	27.10	23.94
Price / Sales	2.94	300.39	517.51	91.94
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	1.72	7.92	10.66	6.14
Net Income	-$66.54M	$23.81M	$3.60B	$331.74M
7 Day Performance	-0.87%	-1.09%	-1.23%	-1.81%
1 Month Performance	21.49%	2.56%	1.11%	-1.44%
1 Year Performance	47.74%	42.16%	23.65%	16.33%

Cytek Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CTKB Cytek Biosciences	3.482 of 5 stars	$4.58 -0.9%	$5.69 +24.2%	+46.3%	$596.64M	$201.49M	N/A	500
AEHR Aehr Test Systems	3.9528 of 5 stars	$72.01 +5.9%	$68.00 -5.6%	+413.3%	$2.14B	$58.97M	N/A	90	Analyst Upgrade Gap Up High Trading Volume
ALMR Alamar Biosciences	3.4629 of 5 stars	$27.05 -1.3%	$30.00 +10.9%	N/A	$1.87B	$87.16M	N/A	222
ALNT Allient	3.9282 of 5 stars	$88.78 +1.7%	$79.83 -10.1%	+117.5%	$1.48B	$554.48M	39.49	2,478	Positive News Analyst Downgrade
EYPT Eyepoint Pharmaceuticals	3.1405 of 5 stars	$13.73 -3.9%	$44.29 +222.5%	+21.5%	$1.20B	$31.37M	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CTKB) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cytek Biosciences (CTKB) Competitors

CTKB vs. AEHR, ALMR, ALNT, EYPT, and TRNS

How does Cytek Biosciences compare to Aehr Test Systems?

Summary

How does Cytek Biosciences compare to Alamar Biosciences?

Summary

How does Cytek Biosciences compare to Allient?

Summary

How does Cytek Biosciences compare to Eyepoint Pharmaceuticals?

Summary

How does Cytek Biosciences compare to Transcat?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTKB vs. The Competition

Cytek Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cytek Biosciences (CTKB) Competitors

CTKB vs. AEHR, ALMR, ALNT, EYPT, and TRNS

How does Cytek Biosciences compare to Aehr Test Systems?

Do analysts recommend AEHR or CTKB?

Do insiders & institutionals have more ownership in AEHR or CTKB?

Does the media refer more to AEHR or CTKB?

Is AEHR or CTKB more profitable?

Which has more risk & volatility, AEHR or CTKB?

Which has better valuation & earnings, AEHR or CTKB?

Summary

How does Cytek Biosciences compare to Alamar Biosciences?

Does the media prefer ALMR or CTKB?

Do analysts prefer ALMR or CTKB?

Is ALMR or CTKB more profitable?

Which has preferable earnings & valuation, ALMR or CTKB?

Do insiders & institutionals hold more shares of ALMR or CTKB?

Summary

How does Cytek Biosciences compare to Allient?

Does the media prefer ALNT or CTKB?

Do institutionals & insiders hold more shares of ALNT or CTKB?

Do analysts rate ALNT or CTKB?

Is ALNT or CTKB more profitable?

Which has more volatility & risk, ALNT or CTKB?

Which has better earnings and valuation, ALNT or CTKB?

Summary

How does Cytek Biosciences compare to Eyepoint Pharmaceuticals?

Do institutionals and insiders hold more shares of CTKB or EYPT?

Is CTKB or EYPT more profitable?

Do analysts rate CTKB or EYPT?

Which has more risk and volatility, CTKB or EYPT?

Which has stronger earnings and valuation, CTKB or EYPT?

Does the media favor CTKB or EYPT?

Summary

How does Cytek Biosciences compare to Transcat?

Is CTKB or TRNS more profitable?

Do insiders and institutionals hold more shares of CTKB or TRNS?

Which has more volatility & risk, CTKB or TRNS?

Which has preferable earnings & valuation, CTKB or TRNS?

Does the media favor CTKB or TRNS?

Do analysts prefer CTKB or TRNS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTKB vs. The Competition

Cytek Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools